SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Sept. 11, 2006--The Institute for OneWorld Health, a nonprofit pharmaceutical company that develops medicines for neglected diseases of the developing world, today announced that the Drug-Controller General of India (DCGI) has approved Paromomycin Intramuscular (IM) Injection for the treatment of Visceral Leishmaniasis (VL), the second most deadly parasitic disease in the world following malaria.
